Anika Therapeutics (ANIK) Misses Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.81 -1.05%
EPS Growth %: -25.0%
Financial Fact:
Interest income (expense), net: 93K
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -25.0%
Financial Fact:
Interest income (expense), net: 93K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.46, $0.01 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $27.2 million versus the consensus estimate of $28.92 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
- Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike
- Amneal gets FDA approval for lanreotide injection, launches immediately
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
